Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.

Korro Bio, Inc.

Korro Bio was founded to turn extraordinary scientific insights into life-altering new treatments for patients. We harness the body’s natural RNA editing machinery to make precise, single-base RNA edits to modulate protein function, addressing the medical needs of patients. Our mission is to rewrite the future for patients living with debilitating disease by repairing the underlying genetic cause.

Atlas Venture

New Enterprise Associates

Alexandria Venture Investments

Wu Capital

MP Healthcare Venture Management

Surveyor Capital

Cormorant Asset Management

Qiming Venture Partners USA

Monashee Investment Management

Invus

Verition Fund Management

Fidelity

Point72

Sixty Degree Capital

Fidelity Management and Research Company

We’re pleased to announce that Korro Bio will be attending the TD Cowen 44th Annual Health Care Conference in Boston.

Our Chief Executive Officer and President, Ram Aiyar, Ph.D., will present on Monday, March 4, 2024, at 2:10 PM ET.

Tune in for a live webcast of the presentation at: https://ir.korrobio.com/

https://lnkd.in/eT4CnDQr

#KorroBio #TDCowen #TDCowenHealthCare Cowen Inc.

#ICYMI, the Korro team attended the Nasdaq Closing Bell Ringing Ceremony on Tuesday. Thank you to Nasdaq for hosting us and your collaboration. Our team had an incredibly humbling moment celebrating our success.

Here's to Korro’s ongoing innovation as we advance #RNAediting.

Missed the livestream? Catch the recording here: https://lnkd.in/eZkjHPRS 

#KorroBio #ClosingBell

We are pleased to announce the key highlights from our presentation at the J.P. Morgan Healthcare Conference last week. We shared data for our lead program in Alpha-1 Antitrypsin Deficiency (AATD) and our pipeline.  

To read more about our recent accomplishments, see the full press release: bit.ly/3HncrAX

To view our corporate presentation, go to: https://bit.ly/3vEWOCx 

#JPM2024 #JPMorganHealthcare #KorroBio

We invite you to tune in to the live webcast today at 11:15 am PT / 2:15 pm ET. Our CEO and President, Ram Aiyar, will share the corporate update at the J.P. Morgan Healthcare Conference. Learn more about our progress in expanding the frontiers of genetic medicines through #RNAediting.

To view the presentation, visit: bit.ly/41VtvHN

To listen to the webcast, go to: https://lnkd.in/g4n4jJqk

Vineet Agarwal Steve Colletti

#JPMorganHealthcare #JPM2024 #KorroBio

	Dec '21	Dec '22	Dec '23
asset turnover
cash per share	14.81 -	6.90 53.39%
company equity multiplier	-3.02 -	-0.74 75.36%	1.30 275.20%
days of inventory outstanding
days of payables outstanding
days of sales outstanding
dividend yield
ebit per revenue
ebt per ebit	0.62 -	0.98 58.98%	0.96 2.39%
effective tax rate	-0.00 -	-0.00 89.21%	-0.00 93.06%
enterprise value multiple	-58.08 -	-26.68 54.06%	1.64 106.16%
fixed asset turnover
free cash flow per share	-4.57 -	-7.36 61.07%
gross profit margin
interest coverage		-499.98 -
inventory turnover
long term debt to capitalization		-0.00 -	0.16 7,438.62%
net income per ebt	1.00 -	1.00 0.01%	1.00 0.02%
net profit margin
operating cash flow per share	-4.01 -	-6.70 67.15%
operating profit margin
payables turnover
pretax profit margin
price fair value	-48.62 -	-15.55 68.01%
receivables turnover
return on assets	-0.17 -	-0.79 357.20%	-0.37 53.47%
return on capital employed	-0.29 -	-0.91 213.38%	-0.42 53.91%
return on equity	0.52 -	0.59 12.64%	-0.48 181.52%
total debt to capitalization		-0.03 -	0.16 600.91%

KRRO

COM:KORROBIO

Korro Bio

Last Close

50.62

22/11 21:00

Market Cap

385.94M

Beta: -

Volume Today

67.40K

Avg: -

Preview